Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 9, 2007, Pages 1066-1072

  Qazilbash, Muzaffar H ^a   Saliba, Rima M ^a   Ahmed, Bilal ^a   Parikh, Gaurav ^a   Mendoza, Floralyn ^a   Ashraf, Noman ^a   Hosing, Chitra ^a   Flosser, Thuy ^a   Weber, Donna M ^a   Wang, Michael ^a   Couriel, Daniel R ^a   Popat, Uday ^a   Kebriaei, Partow ^a   Alousi, Amin M ^a   Anderlini, Paolo ^a   Naeem, Rizwan C ^b   Champlin, Richard E ^a   Giralt, Sergio A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autotransplant; Chromosome abnormalities; Conventional cytogenetics; Deletion 1p; Multiple myeloma; Outcome

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; MELPHALAN; TOPOTECAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DIPLOIDY; DRUG MEGADOSE; FEMALE; HUMAN; HYPERDIPLOIDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL RATE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 34547681819     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.05.014     Document Type: Article

References (42)

1. Hari P., Pasquini M.C., and Vesole D.H. Cure of multiple myeloma-more hype, less reality. Bone Marrow Transplant 37 (2006) 1-18
2. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 28 (2004) 351 1860-1873
3. Attal M., Harousseau J.L., Stoppa A.M., et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 9197
4. Child J.A., Morgan G.J., Davies F.E., et al., Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
5. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
6. Blade J., Rosinol L., Sureda A., et al., Programa para el Estudio de la Terapeutica en Hemopatia Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
7. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
8. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
9. Stewart A.K., and Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 23 (2005) 6339-6344
10. Schilling G., Dierlamm J., and Hossfeld D.K. Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance. Hematol Oncol 23 (2005) 102-107
11. Dewald G.W., Therneau T., Larson D., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 106 (2005) 3553-3558
12. Zandecki M., Lai J.L., and Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 94 (1996) 217-227
13. Bergsagel P.L., and Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 20 (2001) 5611-5622
14. Liebisch P., and Dohner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer 42 (2006) 1520-1529
15. Smadja N.V., Bastard C., Brigaudeau C., Leroux D., Fruchart C., and Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98 (2001) 2229-2238
16. Perez-Simon J.A., Garcia-Sanz R., Tabernero M.D., et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 91 (1998) 3366-3371
17. Wuilleme S., Robillard N., Lode L., et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19 (2005) 275-278
18. Sawyer J.R., Waldron J.A., Jagannath S., et al. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82 (1995) 41-49
19. Sawyer J.R., Lukacs J.L., Thomas E.L., et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 112 (2001) 167-174
20. Tricot G., Barlogie B., Jagannath S., et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86 (1995) 4250-4256
21. Desikan R., Barlogie B., Sawyer J., et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95 (2000) 4008-4010
22. Fonseca R., Blood E.A., Oken M.M., et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99 (2002) 3735-3741
23. Moreau P., Facon T., Leleu X., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100 (2002) 1579-1583
24. Chesi M., Nardini E., Brents L.A., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16 (1997) 260-264
25. Chang H., Sloan S., Li D., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 125 (2004) 64-68
26. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
27. Atkin N.B. Chromosome 1 aberrations in cancer. Cancer Genet Cytogenet 21 (1986) 279-285
28. Shaughnessy Jr. J.D., Zhan F., Burington B.E., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) Nov 14; [Epub ahead of print].
29. Marzin Y., Jamet D., Douet-Guilbert N., et al. Chromosome 1 abnormalities in multiple myeloma. Anticancer Res 26 (2006) 953-959
30. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121 (2003) 749-757
31. Pierre R.V., and Hoagland H.C. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer 30 (1972) 889-894
32. Donato M.L., Aleman A., Champlin R.E., et al. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 45 (2004) 755-759
33. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (1998) 1115-1123
34. Dewald G.W., Broderick D.J., Tom W.W., Hagstrom J.E., and Pierre R.V. The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 18 (1985) 1-10
35. Durie B.G.M., and Salmon S.E. A clinical staging system for multiple myeloma. Cancer 36 (1975) 842-854
36. Qazilbash M.H., Saliba R.M., Hosing C., et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39 (2007) 279-283
37. Qazilbash M.H., Saliba R.M., Aleman A., et al. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47 (2006) 1360-1364
38. Panani A.D., Ferti A.D., Papaxoinis C., Raptis S.A., and Roussos C. Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor. Anticancer Res 24 (2004) 4141-4146
39. Wu K.L., Beverloo B., Lokhorst H.M., et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 136 (2007) 615-623
40. Han S., Semba S., Abe T., et al. Infrequent somatic mutations of the p73 gene in various human cancers. Eur J Surg Oncol 25 (1999) 194-198
41. Rajkumar S.V., Fonseca R., Lacy M.Q., et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant 24 (1999) 497-503
42. Tricot G., Sawyer J.R., Jagannath S., et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15 (1997) 2659-2666